866-997-4948(US-Canada Toll Free)

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 49 Pages

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Pipeline Review, H2 2017

Summary

According to the recently published report Adrenocorticotropic Hormone Receptor-Pipeline Review, H2 2017; Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report Adrenocorticotropic Hormone Receptor-Pipeline Review, H2 2017 outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease), Acromegaly, Amyotrophic Lateral Sclerosis, Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Gouty Arthritis (Gout), Multiple Sclerosis and Nephrotic Syndrome.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Overview
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Companies Involved in Therapeutics Development
Ipsen SA
MallInckrodt Plc
Pfizer Inc
Retrophin Inc
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Drug Profiles
AQB-565-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin Receptor 2 for ACTH-dependent Cushings syndrome and Congenital Adrenal Hyperplasia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Dormant Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Discontinued Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)-Product Development Milestones
Featured News & Press Releases
Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert
Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update
Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims
May 25, 2017: Mallinckrodt Highlights First Patients in Company-Sponsored Prospective Observational Registry on the Use of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse
May 23, 2017: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse
Apr 28, 2017: Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual Meeting
Feb 21, 2017: Mallinckrodt Statement on H.P. Acthar Gel (Repository Corticotropin Injection)
Nov 21, 2016: Mallinckrodt Will Initiate Company-Sponsored Clinical Trial of H.P. Acthar Gel in Treatment of Amyotropic Lateral Sclerosis
Nov 17, 2016: Study Addresses Possible Impact of H.P. Acthar Gel on Use of Corticosteroids Among Patients with Rheumatoid Arthritis, Lupus, and Dermatomyositis/Polymyositis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Ipsen SA, H2 2017
Pipeline by MallInckrodt Plc, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Retrophin Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *